Sentence examples for advanced functional capacity from inspiring English sources

However, the long-term effects of the partial PPARγ agonist bezafibrate on ProBNP level in patients with advanced functional capacity impairment are unknown.

Long-term bezafibrate treatment was not associated with longitudinal ProBNP changes in pre-existing CAD patients with advanced functional capacity impairment.

Future larger-scale controlled clinical trials targeting cardiac function evaluations including ProBNP level as a primary endpoint are required to establish the safety of bezafibrate treatment in CAD patients with advanced functional capacity impairment.

The results of the current study, which indicates no adverse effects of active treatment on longitudinal ProBNP changes, did not support a special restriction for bezafibrate use in patients even with advanced functional capacity impairment such as a NYHA class III.

The current study aimed to investigate the long-term effects of bezafibrate on ProBNP level in patients with pre-existing CAD and advanced functional capacity impairment.

Long-term treatment by bezafibrate was not associated with longitudinal ProBNP changes in patients with pre-existing CAD and advanced functional capacity impairment.

Metabolic and inflammatory parameters were analyzed from stored frozen serum samples obtained from patients with advanced impaired functional capacity who completed a 2-year of prospective, randomized, double-blind, placebo-controlled Bezafibrate Infarction Prevention BIPP) Study period.

There were 134 patients with advanced impaired functional capacity who were included in the BIP study (73 treated by bezafibrate and 61 by placebo); 128 of them survived after a 2-year follow-up (3 deaths were registered both in bezafibrate and placebo group).

Secondary outcome measures include advanced echocardiographic assessment of left ventricular systolic and diastolic function, functional capacity measured by a 6-minute walk test (6MWT), plasma NT-proBNP levels, blood pressure and quality of life estimated by the Minnesota Living with Heart Failure questionnaire (MLHF).

Some risk factors of anxiety and depression symptoms in COPD patients have been widely researched, including younger age, female gender, current smoker status, bronchitic phenotype, more advanced disease, cardiovascular comorbidities, and worse functional capacity and quality of life [ 1, 2, 9, 10].

Sokos et al. reported that a long-term infusion of GLP-1 improves both LVEF and functional capacity in human patients with advanced heart failure [ 30].